Oxygen therapeutics in trauma and surgery

Stephen M. Cohn

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A number of oxygen therapeutics have completed safety trials and are now undergoing efficacy evaluation in multi-center phase III trials in North America and Europe. There are numerous potential advantages of these solutions when compared with packed red blood cells. They are readily available and have a long shelf life; do not require type and cross-matching; are virtually free of viral or bacterial contamination; have a much lower viscosity than blood; and may lack the immunosuppressive effects of blood. These products may also deliver more oxygen per unit mass than an equivalent amount of hemoglobin from red blood cells, providing the potential to sustain life in certain clinical situations. A few problems remain, including short biologic half-life, which may limit the application to times when the patient is most acutely anemic (i.e., in the intraoperative or immediate perioperative phase) or for emergent use. Nevertheless, a safe, effective alternative therapy providing oxygen delivery characteristics comparable to red blood cells may soon be available that could have significant impact on the way that we resuscitate trauma patients.

Original languageEnglish (US)
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume54
Issue number5 SUPPL.
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Erythrocytes
Oxygen
Wounds and Injuries
Blood Viscosity
Immunosuppressive Agents
Complementary Therapies
North America
Half-Life
Hemoglobins
Therapeutics
Safety

Keywords

  • Hemoglobin-based oxygen carriers
  • Oxygen therapeutics
  • Red cell substitutes
  • Surgery
  • Trauma

ASJC Scopus subject areas

  • Surgery

Cite this

Oxygen therapeutics in trauma and surgery. / Cohn, Stephen M.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 54, No. 5 SUPPL., 01.05.2003.

Research output: Contribution to journalArticle

@article{c97f615ec5224bc8bd549172b3ce18a7,
title = "Oxygen therapeutics in trauma and surgery",
abstract = "A number of oxygen therapeutics have completed safety trials and are now undergoing efficacy evaluation in multi-center phase III trials in North America and Europe. There are numerous potential advantages of these solutions when compared with packed red blood cells. They are readily available and have a long shelf life; do not require type and cross-matching; are virtually free of viral or bacterial contamination; have a much lower viscosity than blood; and may lack the immunosuppressive effects of blood. These products may also deliver more oxygen per unit mass than an equivalent amount of hemoglobin from red blood cells, providing the potential to sustain life in certain clinical situations. A few problems remain, including short biologic half-life, which may limit the application to times when the patient is most acutely anemic (i.e., in the intraoperative or immediate perioperative phase) or for emergent use. Nevertheless, a safe, effective alternative therapy providing oxygen delivery characteristics comparable to red blood cells may soon be available that could have significant impact on the way that we resuscitate trauma patients.",
keywords = "Hemoglobin-based oxygen carriers, Oxygen therapeutics, Red cell substitutes, Surgery, Trauma",
author = "Cohn, {Stephen M.}",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "54",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Oxygen therapeutics in trauma and surgery

AU - Cohn, Stephen M.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - A number of oxygen therapeutics have completed safety trials and are now undergoing efficacy evaluation in multi-center phase III trials in North America and Europe. There are numerous potential advantages of these solutions when compared with packed red blood cells. They are readily available and have a long shelf life; do not require type and cross-matching; are virtually free of viral or bacterial contamination; have a much lower viscosity than blood; and may lack the immunosuppressive effects of blood. These products may also deliver more oxygen per unit mass than an equivalent amount of hemoglobin from red blood cells, providing the potential to sustain life in certain clinical situations. A few problems remain, including short biologic half-life, which may limit the application to times when the patient is most acutely anemic (i.e., in the intraoperative or immediate perioperative phase) or for emergent use. Nevertheless, a safe, effective alternative therapy providing oxygen delivery characteristics comparable to red blood cells may soon be available that could have significant impact on the way that we resuscitate trauma patients.

AB - A number of oxygen therapeutics have completed safety trials and are now undergoing efficacy evaluation in multi-center phase III trials in North America and Europe. There are numerous potential advantages of these solutions when compared with packed red blood cells. They are readily available and have a long shelf life; do not require type and cross-matching; are virtually free of viral or bacterial contamination; have a much lower viscosity than blood; and may lack the immunosuppressive effects of blood. These products may also deliver more oxygen per unit mass than an equivalent amount of hemoglobin from red blood cells, providing the potential to sustain life in certain clinical situations. A few problems remain, including short biologic half-life, which may limit the application to times when the patient is most acutely anemic (i.e., in the intraoperative or immediate perioperative phase) or for emergent use. Nevertheless, a safe, effective alternative therapy providing oxygen delivery characteristics comparable to red blood cells may soon be available that could have significant impact on the way that we resuscitate trauma patients.

KW - Hemoglobin-based oxygen carriers

KW - Oxygen therapeutics

KW - Red cell substitutes

KW - Surgery

KW - Trauma

UR - http://www.scopus.com/inward/record.url?scp=0038678069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038678069&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0038678069

VL - 54

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 5 SUPPL.

ER -